Full results & analysis
Available in the Gosset platform where reported.
01
Overview
Phase 3, open-label trial of linezolid in bacterial infection (2 arms), sponsored by Pfizer. Primary endpoint: Percentage of Participants With an Adverse Event. Started Nov 2008; status: terminated.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Linezolid
Patients receiving Linezolid for >= 6 weeks
Matched Control
Patients receiving other antibiotics for >= 6 weeks (Baseline only)
03
Who it enrols
Adult patients receiving linezolid for 6+ weeks or matched controls on other antibiotics. Excludes patients with pre-existing optic/peripheral nerve damage or severe liver disease.
04
Endpoints
Primary
Percentage of Participants With an Adverse Event
Secondary
Percentage of Participants by Clinical Outcome of Infection at End of Study
Beyond the preview
Go deeper on NCT00359632.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00359632.